|
SYS-CON.TV Webcasts
Comments
Did you read today's front page stories & breaking news?
SYS-CON.TV
|
Top Links You Must Click On
From the Wires
With Resolution of Fee-Sharing Dispute, Settlement Funding is Now Available to Avandia Plaintiffs' Attorneys
By: PR Newswire
Feb. 14, 2013 12:05 AM
CRESSKILL, N.J., Feb. 14, 2013 /PRNewswire/ -- Attorneys representing plaintiffs suing GlaxoSmithKline (GSK) over the drug Avandia's side effects have resolved their dispute about sharing fees of $142 million. Over 50,000 lawsuits were filed in US state and federal courts citing GlaxoSmithKline's failure to inform type-2-diabetes patients about Avandia's potentially life-threatening side effects: heart attack and failure, stroke, bone fractures, vision loss, and death. The litigation has taken over ten years, with the lead attorneys alone logging more than 60,000 hours. Yet none of the plaintiffs' attorneys have received any compensation for their time or out-of-pocket expenses. RD Legal Funding is now making immediate post-settlement financing available to ease the Avandia plaintiffs' attorneys' financial burdens. (Photo: http://photos.prnewswire.com/prnh/20110803/NY45278LOGO) The FDA approved the use of rosiglitazone—marketed as Avandia—for the treatment of type-2-diabetes in 1999. Tens of millions of prescriptions were written for the drug which may have caused between 60,000 and 200,000 heart attacks and deaths due to cardiovascular problems in the US alone.
Avandia plaintiffs' attorneys are urged to contact RD Legal Funding, whose unique fee acceleration program will provide them with settlement financing within several days, with no monthly interest or principal payments, as well as no upfront points or fees. No payment of any kind is required until the attorney's settlement fee is received. RD Legal Funding is one of the nation's leading providers of post-settlement financing. For more information call 800-565-5177 or visit http://www.legalfunding.com. SOURCES: SOURCE RD Legal Funding Enterprise Open Source Magazine Latest Stories . . .
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
|
SYS-CON Featured Whitepapers
Most Read This Week |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||